Zevra Therapeutics, Inc. ZVRA Proceeds from disposition of marketable securities and other investments

Proceeds from disposition of marketable securities and other investments at other companies

BioMarin PharmaceuticalsBMRN

——

Other financials

Income statement

See full

Revenue$36.2M+77.5%

Gross profit$34.3M+80.1%

Operating income$52.1M+1,073%

Net income$37.9M+1,323%

EPS (diluted)$0.60+1,100%

Balance sheet

See full

Cash & equivalents$95.6M+156%

Total debt$1.1M-98.1%

Total equity$205.8M+402%

Total assets$278.6M+61.3%

Cash flow

See full

Operating cash flow$6.1M+175%

CapEx$35.0K-64.6%

Free cash flow$6.1M+173%

Valuation

See full

Market cap$782.09M+58.2%

Enterprise value$687.64M+32.5%

P/E6.3×—

P/S6.4×-5.8×

Profitability

See full

Gross margin86.1%+7.2pp

Operating margin-103.9%-43.0pp

Net margin101.6%+60.1pp

FCF margin-75%-30.5pp

Returns & leverage

See full

Return on equity100.7%+60.3pp

Debt / equity0×-1.5×

Current ratio4.9×+1.9×

Where this comes from

Reported directly by Zevra Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments.

The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zevra Therapeutics, Inc.'s proceeds from disposition of marketable securities and other investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Zevra Therapeutics, Inc.'s proceeds from disposition of marketable securities and other investments?: Zevra Therapeutics, Inc. (ZVRA) reported proceeds from disposition of marketable securities and other investments of $93.97M in Q1 2026.
How has Zevra Therapeutics, Inc.'s proceeds from disposition of marketable securities and other investments changed year-over-year?: Zevra Therapeutics, Inc.'s proceeds from disposition of marketable securities and other investments increased by 422.1% year-over-year, from $18M to $93.97M.